Key result
Telmisartan reduced seated systolic blood pressure by 14 mm Hg (high-dose) and 9.7 mm Hg (low-dose) compared to 6 mm Hg with placebo in pediatric patients with hypertension.
Why the study?
Does telmisartan reduce seated systolic blood pressure in pediatric patients with hypertension?
Population
77 pediatric patients (aged 6 to <18 years) with diagnosed hypertension.
Comparison
Telmisartan 1 mg/kg/d or 2 mg/kg/d for 4 weeks. vs Placebo for 4 weeks.
Design
RCT, randomized
Follow-up
4 weeks
Authors
Loading...
Supports telmisartan for pediatric hypertension; extends randomized ARB evidence to children.
RCT (n=77)
Does telmisartan reduce seated systolic blood pressure in pediatric patients with hypertension?
Absolute Event Rate: -14% vs -6%
Telmisartan at doses of 1 mg/kg/d and 2 mg/kg/d effectively lowers systolic blood pressure in pediatric patients with hypertension.
Wells et al. (2010) conducted an RCT in hypertension (n=77). telmisartan vs. placebo was evaluated on change in seated systolic BP (SBP) from baseline to study end. Telmisartan reduced seated systolic blood pressure by 14 mm Hg (high-dose) and 9.7 mm Hg (low-dose) compared to 6 mm Hg with placebo in pediatric patients with hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: